|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2009-9-28
|
|
pubmed:abstractText |
The aim of this study was to assess the efficacy and safety of pegylated interferon (IFN) plus ribavirin (RBV) in human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-coinfected patients with severe immunodeficiency in a clinical cohort. BACKGROUND. A total of 542 HIV-infected patients receiving treatment with pegylated IFN plus RBV from June 2001 through April 2007 were included in this study. The outcome variables were sustained virologic response (SVR) rate and the emergence of AIDS-defining events during HCV infection therapy. SVR rates among patients with a CD4 cell count <or=250 cells/mm(3) at baseline were compared with those among patients with CD4 cell counts >250 cells/mm(3). The association between SVR and potential predictors was analyzed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
pubmed-author:ArponenSariS,
pubmed-author:ColladoAntonioA,
pubmed-author:DelgadoMarcialM,
pubmed-author:GilIgnacio de los SantosIde L,
pubmed-author:González-SerranoMercedesM,
pubmed-author:Gutiérrez-ValenciaAliciaA,
pubmed-author:López-RuzMiguel AngelMA,
pubmed-author:MacíasJuanJ,
pubmed-author:MerinoDoloresD,
pubmed-author:MiraJosé AJA,
pubmed-author:OmarMohamedM,
pubmed-author:PinedaJuan AJA,
pubmed-author:Ríos-VillegasMaría JMJ,
pubmed-author:RiveroAntonioA,
pubmed-author:Torres-TortosaManuelM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e84-91
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19772388-Adult,
pubmed-meshheading:19772388-Antiviral Agents,
pubmed-meshheading:19772388-CD4 Lymphocyte Count,
pubmed-meshheading:19772388-Female,
pubmed-meshheading:19772388-HIV Infections,
pubmed-meshheading:19772388-Hepatitis C, Chronic,
pubmed-meshheading:19772388-Humans,
pubmed-meshheading:19772388-Immunocompromised Host,
pubmed-meshheading:19772388-Interferon-alpha,
pubmed-meshheading:19772388-Male,
pubmed-meshheading:19772388-Polyethylene Glycols,
pubmed-meshheading:19772388-Recombinant Proteins,
pubmed-meshheading:19772388-Ribavirin,
pubmed-meshheading:19772388-Treatment Outcome,
pubmed-meshheading:19772388-Viral Load
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
|
|
pubmed:affiliation |
Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
